A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the management of risk factors for toxicity remains a ch...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:JCO Clin Cancer Inform
المؤلفون الرئيسيون: Seyednasrollah, Fatemeh, Koestler, Devin C., Wang, Tao, Piccolo, Stephen R., Vega, Roberto, Greiner, Russell, Fuchs, Christiane, Gofer, Eyal, Kumar, Luke, Wolfinger, Russell D., Kanigel Winner, Kimberly, Bare, Chris, Neto, Elias Chaibub, Yu, Thomas, Shen, Liji, Abdallah, Kald, Norman, Thea, Stolovitzky, Gustavo, Soule, Howard R., Sweeney, Christopher J., Ryan, Charles J., Scher, Howard I., Sartor, Oliver, Elo, Laura L., Zhou, Fang Liz, Guinney, Justin, Costello, James C.
التنسيق: Artigo
اللغة:Inglês
منشور في: American Society of Clinical Oncology 2017
الموضوعات:
Original Reports
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6874023/
https://ncbi.nlm.nih.gov/pubmed/30657384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/CCI.17.00018
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة